Top Markets
Coin of the day
Anbio Biotechnology Class A Ordinary Shares Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology Class A Ordinary Shares

NNNN
株式のランク #16102
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main,... Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
株価
$7.15
時価総額
$313.60M
変化(1日)
-2.12%
変化(1年)
-84.14%
DE
取引 Anbio Biotechnology Class A Ordinary Shares (NNNN)

カテゴリー

Anbio Biotechnology Class A Ordinary Shares(NNNN)の収益
Sep 2026 時点の収益 TTM: 0
Anbio Biotechnology Class A Ordinary Shares の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Anbio Biotechnology Class A Ordinary Shares の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$11.03B -
US
$34.74B -
FR
- -
JP
$20.84B -
US
- -
CH